OBJECTIVE: Temozolomide (TMZ) is an oral alkylating agent widely used in the treatment of refractory glioma. Its efficacy is limited, however, by poor cancer cell penetration and drug resistance. The present study, therefore, aimed to investigate whether hyperbaric oxygen (HBO) may facilitate drug delivery and enhance the anticancer effect of TMZ. METHODS: Cultured glioma U251 cells were treated with HBO, TMZ, or TMZ + HBO, or were untreated (controls). Rates of growth inhibition, cell death and apoptosis were investigated using the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, propidium iodide staining and flow cytometry, respectively. Protein levels of vascular endothelial growth factor (VEGF) and multidrug resistance-associated protein-1 (MRP-1) were evaluated by enzyme-linked immunosorbent assay. RESULTS: Compared with TMZ or HBO alone, combined treatment with both therapies synergistically inhibited growth and induced apoptosis and death of cultured glioma U251 cells, which was accompanied by a significant decrease in levels of VEGF and MRP-1.
Introduction
Temozolomide (TMZ) is an oral alkylating agent that has been widely used in the treatment of high-grade glioma, which is a major type of malignant brain tumour. The efficacy of TMZ in glioma treatment may X-Y Lu, K Cao, Q-Y Li et al.
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depend on changes in heterochromatin organization and silencing, which lead to apoptosis and senescence. 1 Studies have shown that combining TMZ with other agents can enhance the toxic effects on glioma cells. Drugs such as betulinic acid 2 , lonidamine, 3 and CD437 4 target the mitochondrial pore and function as cytotoxic and cytostatic agents in TMZresistant glioma cells. XL765 is an isoformselective inhibitor of class I phosphatidylinositol-3 kinase and of mammalian target of rapamycin, and combination therapy with XL765 and TMZ has been shown significantly to improve the therapeutic effects on glioma U251 human glioma xenografts. 5 In addition, dihydroartemisinin potentiates the cytotoxic effect of TMZ in rat C6 glioma cells by generating intracellular reactive oxygen species. 6 Research has shown that a combination of TMZ and tamoxifen or hypericin potently inhibits tumour growth through the inhibition of apoptosis, thereby providing a potential treatment for malignant glioma. 7 Despite the effectiveness of TMZ in treating brain tumours, many patients fail to benefit from this drug because of the local hypoxic tumour microenvironment and acquired drug resistance. Despite surgery, radiotherapy and TMZ-based chemotherapy, the prognosis for patients with malignant brain tumours (such as high-grade gliomas) remains poor. Resistance to TMZ is the major barrier to effective therapy. 4 Thus, it is necessary to seek alternative strategies to enhance the anticancer effect of TMZ on refractory malignant brain tumours.
Hyperbaric oxygen (HBO) therapy, which involves the intermittent administration of 100% oxygen at high pressure, has been employed to overcome drug resistance. 8, 9 HBO increases oxygen tension and facilitates oxygen delivery to tissues independent of haemoglobin. HBO may enhance the efficacy of certain therapies that are limited by the hypoxic microenvironment. The short-term effects of HBO include enhanced oxygen delivery to ischaemic tissues, 10 reduction of oedema, vasoconstriction and activation of phagocytosis. 11,12 Long-term effects include neovascularization 13 and stimulation of collagen formation by fibroblasts. 13, 14 Based on the above, it is reasonable to suggest that HBO may enhance the therapeutic effect of TMZ on glioma. Furthermore, research suggests that the effect of HBO may be mediated by inhibiting angiogenesis 15 and lowering multidrug resistance. 16 Vascular endothelial growth factor (VEGF) and multidrug resistanceassociated protein-1 (MRP-1) are two important molecules that are involved in angiogenesis and drug resistance, respectively. VEGF is an important signalling protein involved in vasculogenesis. 17 VEGF enhances micro vascular permeability and is sometimes referred to as 'vascular permeability factor'. 18 Multidrug resistance arises primarily due to the upregulation of proteins from the adenosine triphosphatebinding cassette transporter family. 19 MRP-1 is one important protein believed to be involved in the low efficacy of anticancer therapy. 20 To test the hypothesis that HBO may enhance the therapeutic effect of TMZ on gliomas, and to investigate the possible involvement of angiogenesis and multidrug resistance in such procedures, glioma U251 cells were treated individually with TMZ or HBO (or with a combination of TMZ and HBO) and compared with untreated controls in the present study. Cell growth, death and apoptosis (together with VEGF and MRP-1 protein levels) were investigated.
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Materials and methods
CELL CULTURE PREPARATION AND TREATMENT
Human glioma U251 cells (KeyGen Biotech, Nanjing, China) were cultured in highglucose Dulbecco's Modified Eagle Medium (Gibco BRL, Life Technologies, Gaithersburg, MD, USA) and 10% bovine calf serum (Hangzhou Sijiqing Biological Engineering Materials, Hangzhou, China), pH 7.2, at 37°C in 5% carbon dioxide and 95% humidity. The cells were adherent and were passaged every 2 -3 days by digestion with 0.25% trypsin and ethylenediaminetetraacetic acid at room temperature for 1 -2 min, then centrifuged at 560 g for 3 min. Cultured cells, in good condition at the exponential phase of growth after seven to eight passages, were chosen for the experiment. The cells (1 × 10 4 cells/well in 60-mm 2 tissue culture dishes) were then incubated with 75 µmol/l cobalt chloride (Shanghai Dijin Biological, Shanghai, China) for 24 h, to simulate a hypoxic tumour microenvironment.
After 24 h culture with cobalt chloride, the medium was changed and cells received the following treatments: (i) control, cultured glioma cells without HBO or TMZ treatment; (ii) HBO, cultured glioma cells with only HBO treatment; (iii) TMZ, cultured glioma cells with only TMZ treatment; (iv) TMZ + HBO, cultured glioma cells with both TMZ and HBO treatments.
TREATMENT PROTOCOL
Medical HBO chambers (Yantai Kangbeier Medical Oxygen, Shandong, China) underwent ultraviolet disinfection 30 min before the experiment. Each chamber was flushed for approximately 5 min to increase and maintain the pressure to 2.0 MPa. To ensure 5% carbon dioxide culture conditions, carbon dioxide was added during the procedure. An 80-min HBO treatment was given three times at 12-h intervals. Cells in the control and TMZ alone groups were also put into the HBO chamber, but under normal oxygen pressure. After treatment, cells were transferred back to the 37°C incubator. Excluding the control and HBO treatment only group, TMZ (Jiangsu Tasly Diyi Pharmaceutical Co. Ltd, Jiangsu, China) was added to the glioma cell cultures at a final concentration of 100 µmol/l in culture medium, and incubated for a further 72 h.
ANALYSES OF CELL CYCLE AND DNA DAMAGE
Cell cycle and DNA damage were assessed by propidium iodide (PI) staining (Gibco BRL, Life Technologies) and flow cytometry. After treatment, cells were harvested as described above and centrifuged at 560 g for 3 min. The cells were then fixed in 10 mM phosphate buffered saline (PBS)-methanol solution (pH 7.4) and maintained at 4°C for ≥ 18 h. After one wash with 10 mM PBS, cells were stained with 50 µg/ml PI and 40 µg/ml DNase-free RNase A in 10 mM PBS for 30 min at room temperature in the dark. The DNA fluorescence of PI-stained cells was analysed with a BD FACSCalibur™ flow cytometer (BD Bioscience, San Jose, CA, USA). The percentages of cells in the G 0 /G 1 , S, and G 2 /M stages of the cell cycle were determined with the CellQuest™ software supplied with the equipment.
EVALUATION OF APOPTOSIS
The U251 cells from each treatment were harvested as described above and centrifuged at 560 g for 3 min, followed by two washes with 10 mM PBS. The cells were suspended in 0.3 ml 10 mM PBS, suctioned into a single cell suspension with a syringe, and fixed with 75% cold ethanol. After X-Y Lu, K Cao, Q-Y Li et al.
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incubation overnight at 4°C, cells were centrifuged at 560 g for 3 min, then suspended in an annexin V-fluorescein isothiocyanate-PI reaction solution (Annexin-V-FLUOS staining kit; Roche Diagnostics, Indianapolis, IN, USA), according to the manufacturer's instructions, then incubated for 1 h at room temperature. The percentage of apoptotic cells was then measured by flow cytometry.
TUMOUR CELL GROWTH QUANTIFICATION
Tumour cell growth was quantified using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (Gibco BRL, Life Technologies) according to the manufacturer's instructions. After treatment, glioma U251 cells were harvested as described above, centrifuged at 560 g, and the medium was replaced with 150 µl fresh medium containing 5 mg/ml MTT. After 4 h, the MTT formazan product was dissolved in 150 µl dimethyl sulphoxide for 15 min, and cell proliferation was detected by measuring the absorbance at 570 nm (A-value) with a Sunrise™ microplate reader (Tecan Group, Männedorf, Switzerland). The percentage rate of cell growth inhibition was calculated as (1 -A-value in treatment group / A-value in control group) × 100%.
MEASUREMENT OF PROTEIN LEVELS
The U251 cells from each treatment were harvested as described above, washed with 10 mM PBS, resuspended in protein extraction buffer for 10 min, then centrifuged at 12 000 g for 10 min at 4°C, to obtain total protein (supernatant). Protein concentration was measured using a Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Levels of VEGF and MRP-1 protein in the supernatant were measured using commercially available enzyme-linked immunosorbent assay kits for VEGF (Huamai Bio. Co., Beijing, China) and MRP-1 (Yuanye Bio. Co., Shanghai, China) according to the manufacturers' instructions.
STATISTICAL ANALYSES
All statistical analyses were performed using SPSS ® version 16.0 software (SPSS Inc., Chicago, IL, USA) for Windows ® . Data were presented as the mean ± SD from three repeats of five independent experiments and were analysed using one-way analysis of variance followed by Fisher's least significant difference post hoc test. A P-value < 0.05 was considered to be statistically significant.
Results
Treatment with TMZ or TMZ + HBO was associated with significant growth inhibition (mean ± SD rate of inhibition: TMZ, 50.92 ± 3.98%; TMZ + HBO, 60.17 ± 4.17%; HBO, 9.23 ± 2.51%; P < 0.05 TMZ and TMZ + HBO versus HBO). Flow cytometry analysis of the cell cycle showed an increased number of cells in the G 2 /M phase (Figs 1A -1E ) for all treatment groups versus the control group. HBO treatment did not cause a significant change in the percentage of cells in the G 0 /G 1 , G 2 /M, or S phases versus controls (Figs 1B, 1E ). Treatment with TMZ (P < 0.05; Figs 1C, 1E) and with TMZ + HBO (P < 0.05; Figs 1D, 1E ) significantly increased the percentage of cells in the G 2 /M phase and significantly decreased the percentage of cells in the S phase, compared with the control group.
All treatments were associated with a significant increase in the mean ± SD rate of apoptosis compared with no treatment: control, 5.84 ± 0.65%; HBO, 9.51 ± 0.72%; TMZ, 14.67 ± 1.52%; TMZ + HBO, 25.23 ± 2.28%; P < 0.05 for all groups versus control (Figs 2A -2E ). Combined treatment with TMZ + HBO induced significantly more X-Y Lu, K Cao, Q-Y Li et al.
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Treatment with HBO, TMZ and TMZ + HBO induced significant cell death compared with no treatment (Figs 3A -3D) . The mean ± SD rates of cell death were: control, 9.13 ± 0.76%; HBO, 15.12 ± 1.87%; TMZ, 40.81 ± 3.32%; TMZ + HBO: 62.54 ± 5.23% (P < 0.05 for all groups versus control). Combined treatment with TMZ and HBO induced significantly more cell death than TMZ alone (P < 0.05).
The VEGF protein levels for the control, HBO, TMZ and TMZ + HBO groups were 750.45 ± 56.72 ng/l, 417.71 ± 16.25 ng/l, 684.21 ± 40.28 ng/l and 350.62 ± 20.86 ng/l, respectively. The HBO and TMZ + HBO treatments resulted in significant decreases in VEGF levels compared with the control group (P < 0.05). There was no significant difference between the TMZ and control groups.
The MRP-1 levels for the control, HBO, TMZ and TMZ + HBO groups were 1535.28 ± 34.98 ng/l, 1068.81 ± 50.03 ng/l, 1652.45 ± 30.58 ng/l, and 835.56 ± 54.26 ng/l, respectively. The HBO and TMZ + HBO treatments significantly decreased MRP-1 levels compared with the control group (P < 0.05). The level of MRP-1 in the TMZ group was slightly higher than that in the control group, although this difference was not statistically significant. 
Discussion
The present study investigated the effect of treatment with HBO alone, or in combination with TMZ, on proliferation and apoptosis of the glioma U251 cell line. HBO alone or in combination with TMZ was found to inhibit cell proliferation and induce apoptosis. The effect of the combined treatment was superior to that of TMZ treatment alone. The significant reduction in VEGF and MRP-1 protein levels in response to HBO treatment indicated that the potential mechanisms of HBO treatment might include decreased angiogenesis and lowering of multidrug resistance. VEGF and MRP-1 levels in the HBO and TMZ + HBO groups were not significantly different, suggesting that HBO treatment contributed more to the decreases in VEGF and MRP-1 than TMZ treatment. For decades the mainstream treatment for malignant glioma has been radiotherapy followed by chemotherapy. TMZ is one of the few cytotoxic cancer chemotherapeutic agents in use that can cross the blood-brain C TMZ Effect of TMZ and HBO on malignant glioma barrier. 21 TMZ was shown significantly to improve the survival of patients with newly diagnosed glioblastoma when administered concomitantly with radiotherapy and as maintenance therapy thereafter. 22 The efficacy of TMZ in treating glioma is, however, limited by drug resistance. It is widely accepted that hypoxia promotes local tumour growth and angiogenesis, and that invasion reduces the effects of chemotherapy and radiotherapy. 23 -25 HBO increases oxygen tension in tumours, 23,26 -28 thereby improving the radiation response in glioma. 29, 30 Consistent with the literature, the present study verified that HBO can enhance the effect of chemotherapy with TMZ by inhibiting tumour cell proliferation and inducing apoptosis and death. In addition, the hypothesis that HBO can be used as adjuvant therapy to enhance the anticancer effect of TMZ was verified.
The present study showed that HBO treatment was able to induce apoptosis. This has also been observed in transplanted gliomas in nude rats, 31 where induction of apoptosis was indicated by an elevated number of terminal deoxynucleotidyl tranferase dUTP nick-end labelling-positive apoptotic tumour cells. The mechanisms relating to the effect of HBO on tumour growth are still not well known, however the free oxygen radical level has been reported to be elevated after normobaric and HBO therapy, 32 which may exceed the 33 Further studies are required to reveal the definitive mechanisms of apoptosis under HBO treatment.
To investigate the potential cellular mechanisms of HBO treatment, levels of VEGF and MRP-1 were measured and were shown to be decreased in cells receiving HBO treatment. An in vivo study has described the biological effects of HBO treatment on BT4C rat glioma xenografts. 31 Increased partial pressure of oxygen in experimental gliomas, following normobaric and moderate HBO therapy, caused a significant reduction in tumour growth. 31 This process was characterized by enhanced cell death and reduced vascular density, similar to the present study. The previous study also showed that the effect of HBO on gliomas was characterized by a downregulation of genes known to have implications in tumour growth and neovascularization. 31 Thus, HBO greatly improves oxygen perfusion in tumours and alters the hypoxic microenvironment, which may affect the tumours by inducing cell death and reducing vascular density.
Another reason for the poor survival rate associated with gliomas is the development of multidrug resistance. 34 -37 Upregulation of one or more forms of MRP has been demonstrated in many cancer cell lines. 38 Further studies have indicated that MRP is present at high levels in glioma cells, suggesting that MRP may be the primary drug resistance gene for multidrug resistance in glioma. 39 Although not verified by data from glioma cells, the effect of HBO on MRP-2 protein has been shown in vitro in rat primary hepatocytes. 40 That study showed that HBO stimulated hepatocytes to proliferate, and that HBO normalized MRP-2 localization to the apical membrane, which could dilate the bile canaliculi. 40 In conclusion, the present study showed that HBO in combination with TMZ can synergistically retard cell growth and induce apoptosis in glioma cell cultures, compared with either treatment alone, possibly by adjusting the hypoxic microenvironment, reducing the generation of blood vessels and restraining multidrug resistance. The inferior effect of HBO as stand-alone treatment compared with TMZ suggests that HBO should be used as an adjuvant therapy combined with chemotherapy or radiotherapy. In vivo animal or human studies are required to prove the effect of HBO on glioma.
